Annie Luetkemeyer

8.8k total citations
20 papers, 580 citations indexed

About

Annie Luetkemeyer is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, Annie Luetkemeyer has authored 20 papers receiving a total of 580 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 12 papers in Epidemiology and 12 papers in Hepatology. Recurrent topics in Annie Luetkemeyer's work include Hepatitis C virus research (12 papers), HIV/AIDS drug development and treatment (9 papers) and Tuberculosis Research and Epidemiology (6 papers). Annie Luetkemeyer is often cited by papers focused on Hepatitis C virus research (12 papers), HIV/AIDS drug development and treatment (9 papers) and Tuberculosis Research and Epidemiology (6 papers). Annie Luetkemeyer collaborates with scholars based in United States, Australia and United Kingdom. Annie Luetkemeyer's co-authors include Diane V. Havlir, Edwin D. Charlebois, Laura Flores, Jeffrey N. Martin, Steven G. Deeks, David R. Bangsberg, Gabriel Chamie, Phyllis C. Tien, C. Bradley Hare and John Stansell and has published in prestigious journals such as Hepatology, American Journal of Respiratory and Critical Care Medicine and Clinical Infectious Diseases.

In The Last Decade

Annie Luetkemeyer

20 papers receiving 565 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annie Luetkemeyer United States	13	415	410	195	188	40	20	580
Maximilian C. Aichelburg Austria	14	382 0.9×	250 0.6×	195 1.0×	147 0.8×	43 1.1×	32	533
Giulia Tositti Italy	12	334 0.8×	166 0.4×	271 1.4×	74 0.4×	64 1.6×	28	607
Mina John Australia	11	276 0.7×	223 0.5×	165 0.8×	84 0.4×	125 3.1×	29	526
G. Antonucci Italy	12	495 1.2×	294 0.7×	337 1.7×	107 0.6×	106 2.6×	36	655
Vincent Jeantils France	11	263 0.6×	252 0.6×	121 0.6×	78 0.4×	116 2.9×	22	461
Assunta Navarra Italy	15	311 0.7×	470 1.1×	34 0.2×	177 0.9×	37 0.9×	34	554
Pietro Vittozzi Italy	8	124 0.3×	296 0.7×	66 0.3×	49 0.3×	16 0.4×	12	437
Wang-Da Liu Taiwan	13	118 0.3×	172 0.4×	40 0.2×	144 0.8×	48 1.2×	49	452
Julio Mendez United States	16	551 1.3×	324 0.8×	67 0.3×	98 0.5×	56 1.4×	33	776
Paola Mencarini Italy	15	351 0.8×	338 0.8×	21 0.1×	102 0.5×	57 1.4×	44	576

Countries citing papers authored by Annie Luetkemeyer

Since Specialization

Citations

This map shows the geographic impact of Annie Luetkemeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annie Luetkemeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annie Luetkemeyer more than expected).

Fields of papers citing papers by Annie Luetkemeyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annie Luetkemeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annie Luetkemeyer. The network helps show where Annie Luetkemeyer may publish in the future.

Co-authorship network of co-authors of Annie Luetkemeyer

This figure shows the co-authorship network connecting the top 25 collaborators of Annie Luetkemeyer. A scholar is included among the top collaborators of Annie Luetkemeyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annie Luetkemeyer. Annie Luetkemeyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morris, Meghan D., et al.. (2023). Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations. JAMA Network Open. 6(10). e2338792–e2338792. 19 indexed citations

Bainbridge, Emma, Olusegun O. Soge, Cole Grabow, et al.. (2021). 163. High Prevalence of Urogenital and Rectal Mycoplasma genitalium in U.S. MSM with a History of STIs in the Last Year. Open Forum Infectious Diseases. 8(Supplement_1). S98–S99. 1 indexed citations

Sulkowski, Mark, Annie Luetkemeyer, David Wyles, et al.. (2020). Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non‐adherence. Alimentary Pharmacology & Therapeutics. 51(12). 1384–1396. 22 indexed citations

Graham, Barbara, Kristofor J. Webb, Laura V. Ashton, et al.. (2019). A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome. International Journal of Infectious Diseases. 84. 30–38. 20 indexed citations

Facente, Shelley N., et al.. (2018). Localized US Efforts to Eliminate Hepatitis C. Infectious Disease Clinics of North America. 32(2). 293–311. 11 indexed citations

Rockstroh, JK, Karine Lacombe, Chloe Orkin, et al.. (2018). Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study. International Journal of Infectious Diseases. 73. 372–372. 3 indexed citations

Nelson, Mark, Rafael Rubio, Adriano Lazzarin, et al.. (2017). Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. Journal of Interferon & Cytokine Research. 37(3). 103–111. 13 indexed citations

Rockstroh, JK, Karine Lacombe, Rolando M. Viani, et al.. (2017). Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study. Journal of Hepatology. 66(1). S102–S103. 16 indexed citations

Wyles, David, Heiner Wedemeyer, Ziv Ben‐Ari, et al.. (2017). Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. Hepatology. 66(6). 1794–1804. 19 indexed citations

10.

Dore, G.J., Jason Grebely, Frederick L. Altice, et al.. (2017). O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study. Journal of Virus Eradication. 3. 8–8. 5 indexed citations

11.

Wyles, David, Norbert Bräu, Eric S. Daar, et al.. (2016). Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study. Journal of Hepatology. 64(2). S188–S189. 24 indexed citations

12.

Luetkemeyer, Annie, Cheryl McDonald, Moti Ramgopal, et al.. (2015). 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. Open Forum Infectious Diseases. 2(suppl_1). 1 indexed citations

13.

Luetkemeyer, Annie, Darlene Lu, Beatriz Grinsztejn, et al.. (2015). Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-based Antituberculosis Therapy in the STRIDE Study. Clinical Infectious Diseases. 60(12). 1860–1863. 21 indexed citations

14.

Marks, Kristen, Douglas Kitch, Raymond T. Chung, et al.. (2013). Pilot Study of Pioglitazone Before HCV Retreatment in HIV/HCV Genotype 1–Infected Subjects With Insulin Resistance and Previous Nonresponse to Peginterferon and Ribavirin Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 65(3). 345–349. 1 indexed citations

15.

Nahid, Payam, Jussi Saukkonen, William R. Mac Kenzie, et al.. (2011). Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap. American Journal of Respiratory and Critical Care Medicine. 184(8). 972–979. 41 indexed citations

16.

Chamie, Gabriel, Annie Luetkemeyer, Alphonse Okwera, et al.. (2010). Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata.. PubMed. 14(10). 1295–302. 61 indexed citations

17.

Chamie, Gabriel, Annie Luetkemeyer, Edwin D. Charlebois, & Diane V. Havlir. (2010). Tuberculosis as Part of the Natural History of HIV Infection in Developing Countries. Clinical Infectious Diseases. 50(s3). S245–S254. 29 indexed citations

18.

Luetkemeyer, Annie, Edwin D. Charlebois, Laura Flores, et al.. (2007). Comparison of an Interferon-γ Release Assay with Tuberculin Skin Testing in HIV-infected Individuals. American Journal of Respiratory and Critical Care Medicine. 175(7). 737–742. 168 indexed citations

19.

Swaminathan, Soumya, et al.. (2006). Antiretroviral therapy and TB. Tropical Doctor. 36(2). 73–79. 10 indexed citations

20.

Luetkemeyer, Annie, C. Bradley Hare, John Stansell, et al.. (2005). Clinical Presentation and Course of Acute Hepatitis C Infection in HIV-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 41(1). 31–36. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact